Foundation Resource Management Inc. Raises Holdings in Sanofi (NASDAQ:SNY)

Foundation Resource Management Inc. boosted its holdings in shares of Sanofi (NASDAQ:SNYGet Rating) by 0.3% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 249,546 shares of the company’s stock after acquiring an additional 798 shares during the quarter. Sanofi accounts for approximately 2.2% of Foundation Resource Management Inc.’s holdings, making the stock its 16th biggest holding. Foundation Resource Management Inc.’s holdings in Sanofi were worth $12,485,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of SNY. Boston Partners boosted its stake in Sanofi by 62.3% in the first quarter. Boston Partners now owns 11,272,368 shares of the company’s stock valued at $580,302,000 after acquiring an additional 4,328,799 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Sanofi by 276.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after buying an additional 2,468,271 shares during the period. Bank of America Corp DE lifted its stake in shares of Sanofi by 14.4% during the first quarter. Bank of America Corp DE now owns 12,051,921 shares of the company’s stock worth $618,746,000 after buying an additional 1,512,434 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Sanofi by 29.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,227,680 shares of the company’s stock worth $111,607,000 after buying an additional 506,752 shares during the period. Finally, Aaron Wealth Advisors LLC lifted its stake in shares of Sanofi by 5,487.1% during the first quarter. Aaron Wealth Advisors LLC now owns 415,289 shares of the company’s stock worth $8,089,000 after buying an additional 407,856 shares during the period. 10.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on SNY shares. Morgan Stanley lowered their price objective on shares of Sanofi from €112.00 ($114.29) to €93.00 ($94.90) in a research note on Thursday, September 8th. TheStreet downgraded shares of Sanofi from a “b-” rating to a “c+” rating in a research report on Thursday, September 15th. UBS Group downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 9th. JPMorgan Chase & Co. boosted their target price on shares of Sanofi from €105.00 ($107.14) to €115.00 ($117.35) in a research report on Monday, August 1st. Finally, Cheuvreux downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Wednesday, August 24th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $105.38.

Sanofi Stock Performance

SNY traded down $0.79 on Friday, reaching $38.34. The stock had a trading volume of 97,644 shares, compared to its average volume of 2,093,357. Sanofi has a 12-month low of $38.66 and a 12-month high of $58.10. The company has a current ratio of 1.29, a quick ratio of 0.34 and a debt-to-equity ratio of 0.22. The business’s 50-day moving average price is $43.81 and its two-hundred day moving average price is $48.70. The company has a market cap of $97.19 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53.

Sanofi (NASDAQ:SNYGet Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.07. The company had revenue of $10.78 billion during the quarter, compared to analysts’ expectations of $10.32 billion. Sanofi had a net margin of 16.60% and a return on equity of 25.99%. Sell-side analysts forecast that Sanofi will post 4.14 earnings per share for the current year.

Sanofi Company Profile

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Read More

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYGet Rating).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.